Skip to main content
Premium Trial:

Request an Annual Quote

IP Roundup: NabSys, IMDx, Affymetrix, and Illumina Win US Patents


NabSys has been awarded US Patent No. 8,882,980, "Use of longitudinally displaced nanoscale electrodes for voltage sensing of biomolecules and other analytes in fluidic channels."

Xinsheng Ling, Barrett Bready, John Oliver, Maryam Jouzi, and Leo Petrossian are named as the inventors.

Intelligent Medical Devices (IMDx) has been awarded US Patent No. 8,883,417, "Clinically intelligent diagnostic methods utilizing micromixers disposed in wells."

Alice Jacobs, Boris Nikolic, and Vineet Gupta are named as the inventors.

Affymetrix has been awarded US Patent No. 8,883,691, "Encoded microparticles."

Randall True is named as the inventor.

Illumina has been awarded US Patent No. 8,884,211, "Confocal imaging methods and apparatus."

Wenyi Feng, Theofilos Kotseroglou, Mark Wang, Alexander Triener, Diping Che, and Robert Kain are named as the inventors.

Illumina has also been awarded US Patent No. 8,883,424, "Use of microfluidic systems in the detection of target analytes using microsphere arrays."

Mark Chee, Todd Dickinson, Kevin Gunderson, and Don O'Neil are named as the inventors.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.